Definitive Healthcare Corp. (NASDAQ:DH) Stake Reduced by Jane Street Group LLC

Jane Street Group LLC reduced its holdings in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 65.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,517 shares of the company's stock after selling 75,310 shares during the quarter. Jane Street Group LLC's holdings in Definitive Healthcare were worth $162,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Ieq Capital LLC purchased a new position in shares of Definitive Healthcare in the fourth quarter valued at $51,000. KLP Kapitalforvaltning AS purchased a new position in Definitive Healthcare in the 4th quarter valued at about $54,000. Two Sigma Securities LLC acquired a new stake in shares of Definitive Healthcare during the fourth quarter valued at about $56,000. Quantbot Technologies LP increased its position in shares of Definitive Healthcare by 5,305.5% during the fourth quarter. Quantbot Technologies LP now owns 17,730 shares of the company's stock worth $73,000 after acquiring an additional 17,402 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Definitive Healthcare in the fourth quarter worth about $76,000. Institutional investors and hedge funds own 98.67% of the company's stock.

Definitive Healthcare Stock Performance

DH traded up $0.09 during trading hours on Tuesday, hitting $3.75. The company's stock had a trading volume of 725,229 shares, compared to its average volume of 793,335. The company has a 50-day simple moving average of $2.97 and a 200 day simple moving average of $3.74. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $557.41 million, a PE ratio of -1.21, a PEG ratio of 4.06 and a beta of 1.58. Definitive Healthcare Corp. has a fifty-two week low of $2.15 and a fifty-two week high of $6.27.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $59.19 million for the quarter, compared to analyst estimates of $56.20 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The company's quarterly revenue was down 6.8% compared to the same quarter last year. During the same period last year, the company earned $0.08 earnings per share. As a group, sell-side analysts expect that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DH. Barclays lowered their price objective on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research note on Monday, March 3rd. BTIG Research cut shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a report on Friday, May 9th. The Goldman Sachs Group increased their price objective on shares of Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research note on Monday, May 12th. Finally, Wall Street Zen downgraded shares of Definitive Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, May 31st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $5.10.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.